- Home
- JL vs ATHA Comparison
JL vs ATHA Comparison
Compare JL & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- ATHA
- Stock Information
- Founded
- JL 1985
- ATHA 2011
- Country
- JL Hong Kong
- ATHA United States
- Employees
- JL N/A
- ATHA N/A
- Industry
- JL
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- JL
- ATHA Health Care
- Exchange
- JL NYSE
- ATHA Nasdaq
- Market Cap
- JL 10.0M
- ATHA 10.6M
- IPO Year
- JL 2024
- ATHA 2020
- Fundamental
- Price
- JL $6.04
- ATHA $0.31
- Analyst Decision
- JL
- ATHA Buy
- Analyst Count
- JL 0
- ATHA 4
- Target Price
- JL N/A
- ATHA $11.25
- AVG Volume (30 Days)
- JL 18.4K
- ATHA 1.3M
- Earning Date
- JL 07-07-2025
- ATHA 07-31-2025
- Dividend Yield
- JL N/A
- ATHA N/A
- EPS Growth
- JL N/A
- ATHA N/A
- EPS
- JL 0.54
- ATHA N/A
- Revenue
- JL $32,831,195.00
- ATHA N/A
- Revenue This Year
- JL N/A
- ATHA N/A
- Revenue Next Year
- JL N/A
- ATHA N/A
- P/E Ratio
- JL $11.29
- ATHA N/A
- Revenue Growth
- JL 7.72
- ATHA N/A
- 52 Week Low
- JL $2.33
- ATHA $0.22
- 52 Week High
- JL $13.41
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- JL 66.11
- ATHA 49.52
- Support Level
- JL $5.63
- ATHA $0.29
- Resistance Level
- JL $6.43
- ATHA $0.35
- Average True Range (ATR)
- JL 0.41
- ATHA 0.03
- MACD
- JL -0.04
- ATHA -0.00
- Stochastic Oscillator
- JL 71.08
- ATHA 14.10
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.